Acrivon Therapeutics, Inc.

NasdaqGM:ACRV Stock Report

Market Cap: US$206.1m

Acrivon Therapeutics Valuation

Is ACRV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ACRV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ACRV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ACRV's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACRV?

Key metric: As ACRV is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ACRV. This is calculated by dividing ACRV's market cap by their current book value.
What is ACRV's PB Ratio?
PB Ratio1x
BookUS$196.89m
Market CapUS$206.12m

Price to Book Ratio vs Peers

How does ACRV's PB Ratio compare to its peers?

The above table shows the PB ratio for ACRV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average41.3x
NKTX Nkarta
0.4x-8.3%US$176.4m
TCRX TScan Therapeutics
0.8x2.9%US$173.2m
LYEL Lyell Immunopharma
0.4x-14.9%US$194.9m
MRSN Mersana Therapeutics
163.7x28.8%US$171.7m
ACRV Acrivon Therapeutics
1x13.5%US$206.1m

Price-To-Book vs Peers: ACRV is good value based on its Price-To-Book Ratio (1x) compared to the peer average (41.3x).

Price to Book Ratio vs Industry

How does ACRV's PB Ratio compare vs other companies in the US Biotechs Industry?

56 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.3x35.7%US$653.54m
LYEL Lyell Immunopharma
0.4x-14.9%US$194.87m
ACET Adicet Bio
0.4x3.1%US$81.80m
IMAB I-Mab
0.4x2.7%US$76.60m
ACRV 1.0xIndustry Avg. 1.9xNo. of Companies77PB01.63.24.86.48+
56 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ACRV is good value based on its Price-To-Book Ratio (1x) compared to the US Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is ACRV's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACRV PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ACRV's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ACRV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$6.62
US$21.11
+218.9%
19.7%US$30.00US$16.00n/a9
Dec ’25US$7.58
US$21.56
+184.4%
21.0%US$30.00US$16.00n/a9
Nov ’25US$8.01
US$21.67
+170.5%
21.5%US$30.00US$16.00n/a9
Oct ’25US$6.98
US$21.67
+210.4%
21.5%US$30.00US$16.00n/a9
Sep ’25US$9.49
US$22.00
+131.8%
18.6%US$30.00US$17.00n/a8
Aug ’25US$7.81
US$22.38
+186.5%
17.2%US$30.00US$17.00n/a8
Jul ’25US$5.86
US$22.38
+281.8%
17.2%US$30.00US$17.00n/a8
Jun ’25US$7.72
US$22.38
+189.8%
17.2%US$30.00US$17.00n/a8
May ’25US$8.23
US$22.13
+168.8%
17.7%US$30.00US$17.00n/a8
Apr ’25US$7.25
US$19.13
+163.8%
23.0%US$26.00US$12.00n/a8
Mar ’25US$5.70
US$19.63
+244.3%
24.4%US$26.00US$12.00n/a8
Feb ’25US$3.86
US$20.43
+429.2%
22.5%US$26.00US$12.00n/a7
Jan ’25US$4.92
US$20.43
+315.2%
22.5%US$26.00US$12.00US$6.027
Dec ’24US$4.41
US$22.00
+398.9%
15.2%US$26.00US$17.00US$7.587
Nov ’24US$5.08
US$22.71
+347.1%
13.3%US$26.00US$17.00US$8.017
Oct ’24US$9.56
US$22.50
+135.4%
14.2%US$26.00US$17.00US$6.986
Sep ’24US$11.71
US$23.60
+101.5%
9.5%US$26.00US$20.00US$9.495
Aug ’24US$12.46
US$23.80
+91.0%
8.1%US$26.00US$21.00US$7.815
Jul ’24US$12.96
US$23.80
+83.6%
8.1%US$26.00US$21.00US$5.865
Jun ’24US$12.42
US$22.67
+82.5%
13.6%US$26.00US$17.00US$7.726
May ’24US$12.42
US$22.25
+79.1%
15.0%US$26.00US$17.00US$8.234
Apr ’24US$12.69
US$21.50
+69.4%
20.9%US$26.00US$17.00US$7.252
Mar ’24US$20.63
US$21.00
+1.8%
19.0%US$25.00US$17.00US$5.702
Feb ’24US$16.40
US$21.00
+28.0%
19.0%US$25.00US$17.00US$3.862
Jan ’24US$11.52
US$21.00
+82.3%
19.0%US$25.00US$17.00US$4.922

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 11:21
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Acrivon Therapeutics, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Evan SeigermanBMO Capital Markets Equity Research
Etzer DaroutBMO Capital Markets Equity Research
Emily BodnarH.C. Wainwright & Co.